Nanjing King-friend Biochemical Pharmaceutical Co., Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd - overview
Established
2000
Location
Nanjing, Jiangsu, China
Primary Industry
Pharmaceuticals
About
Nanjing King-friend Biochemical Pharmaceutical Co. , Ltd focuses on developing and manufacturing biopharmaceuticals and health supplements, offering innovative medical solutions aimed at enhancing patient outcomes through advanced therapeutic products. Founded in 2000 in Nanjing, China, Nanjing King-friend Biochemical Pharmaceutical Co. , Ltd specializes in biopharmaceuticals.
The company successfully transitioned to public trading with an IPO on July 19, 2017, raising CNY 457. 8 million by selling 63. 5 million shares at CNY 7. 21 each.
The founder's background is not specified, and there are currently no records of subsidiaries or previous mergers. Nanjing King-friend Biochemical Pharmaceutical Co. , Ltd specializes in the development and manufacturing of pharmaceutical products, particularly in biopharmaceuticals and health supplements. Their core offerings include biologics such as monoclonal antibodies and recombinant proteins, targeting diseases like cancer and autoimmune disorders.
The company primarily serves hospitals, healthcare providers, and research institutions, with distribution channels extending to Europe and North America, supporting clinical research and patient care. In 2021, Nanjing King-friend Biochemical Pharmaceutical Co. , Ltd reported a revenue of CNY 571,441,346. 7 with an EBITDA of CNY 197,650,367.
7. Revenue is generated through direct sales to healthcare providers and research institutions, utilizing a B2B model for consistent product supply. Pricing aligns with the advanced technology and efficacy of their therapeutics. Nanjing King-friend Biochemical Pharmaceutical Co.
, Ltd plans to expand its product line with new biopharmaceuticals to be launched by 2024, targeting specific therapeutic areas. They aim to penetrate new markets in Southeast Asia and Latin America within the next three years. The recent IPO funding of CNY 457. 8 million will support these initiatives, facilitating research and development for upcoming products and enhancing market entry strategies.
Current Investors
Vivo Capital, Oriental Fortune Capital, MPCi
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Specialty Pharmaceuticals, Biomaterials
Website
www.nkf-pharma.com
Verticals
Manufacturing
Company Stage
Mature
Total Amount Raised
Subscriber access only
Nanjing King-friend Biochemical Pharmaceutical Co., Ltd - financials
| Fiscal Year Ended | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 |
|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 416,121,100 | 468,728,000 | 581,913,000 | 1,075,238,807.1 | 1,698,619,784.7 | - | - | - |
| % Revenue Growth (YoY) | - | 12.6% | 24.1% | 84.8% | 58.0% | - | - | - |
| EBITDA (USD) | 78,797,400 | 124,370,600 | 312,546,400 | 389,272,571 | 500,295,297.4 | - | - | - |
| Operating Income (USD) | 59,275,700 | 98,594,200 | 161,075,500 | 348,099,536.4 | 460,118,477 | - | - | - |
| Operating Margin | 14.2% | 21.0% | 27.7% | 32.4% | 27.1% | - | - | - |
| % EBITDA Margin | 18.9% | 26.5% | 53.7% | 36.2% | 29.5% | - | - | - |
| NET Income (USD) | 50,459,500 | 87,553,500 | 257,239,600 | 314,222,399.4 | 424,549,136.7 | - | - | - |
| % Net Margin | 12.1% | 18.7% | 44.2% | 29.2% | 25.0% | - | - | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.